Health economic assessment of Sarclisa in multiple myeloma

TLV

6 September 2021 - TLV has produced a health economic assessment for the regions for the drug Sarclisa (isatuximab) in combination with pomalidomide and dexamethasone. 

The investigation concerns the treatment of adult patients with recurrent and refractory multiple myeloma, who have previously undergone at least two treatments, where previous treatment included lenalidomide and a proteasome inhibitor and a demonstrated disease progression during the last treatment.

Read TLV News [Swedish]

Michael Wonder

Posted by:

Michael Wonder